Sanofi to showcase data from its transformative oncology pipeline at 2021 ASCO Meeting
20 May 2021 - 7:45AM
Sanofi to showcase data
from its transformative
oncology pipeline at 2021 ASCO Meeting
- Early clinical data for investigational oral selective estrogen
receptor (SERD), amcenestrant, show potential to become a new
endocrine backbone therapy in ER+ HER2- breast cancer
- Data that reinforce Libtayo® (cemiplimab-rwlc) as a standard of
care in advanced non-melanoma skin cancer and advanced non-small
cell lung cancer, including new data in historically
underrepresented patients with brain metastases
- Longer term data and new analyses for Sarclisa®
(isatuximab-irfc) further strengthen efficacy profile, including
for elderly patients and patients with high-risk cytogenetic
abnormalities
PARIS –
May 19,
2021 – New research being presented at
the upcoming virtual American Society of Clinical Oncology (ASCO)
Annual Meeting from June 4-8 highlights Sanofi’s transformative
science and commitment to patient care across difficult-to-treat
cancers, including multiple myeloma, skin, lung and breast
cancers.“Our pipeline of innovative investigational medicines
continues to expand, supporting our goal to address critical gaps
in treatment options for patients with cancers of high unmet need,”
says Peter C. Adamson, Global Development Head, Oncology at Sanofi.
“We look forward to presenting the latest data across our oncology
portfolio and pipeline in four key areas – multiple myeloma, skin
cancers, lung cancers and breast cancer, including data supporting
the potential for amcenestrant to become a best-in-class oral
endocrine backbone therapy.”
Early clinical data
for amcenestrant, our
investigational oral
selective estrogen receptor degrader
(SERD),
show potential
to become a
new endocrine backbone therapy
in ER+ HER2- breast
cancer*
- Abstract 1058: AMEERA 1: Phase 1/2
study of amcenestrant (SAR439859), an oral selective estrogen
receptor (ER) degrader (SERD), with palbociclib (palbo) in
postmenopausal women with ER+/human epidermal growth factor
receptor 2-negative (HER2−) metastatic breast cancer (MBC)
- Abstract TPS1104: AMEERA-5: A
randomized, double-blind phase 3 study of amcenestrant (SAR439859)
+ palbociclib versus letrozole + palbociclib for previously
untreated ER+/HER2- advanced breast cancer (Trial in Progress)
Click here to read the full amcenestrant data
press release issued by Sanofi.
Data analyses reinforce
Libtayo® (cemiplimab-rwlc)
as a standard of care in advanced
non-melanoma skin cancer indications and in advanced non-small cell
lung cancer, including new data
in historically underrepresented patients with brain
metastases
Libtayo in Non-melanoma Skin Cancer
- Abstract 9547: Checkpoint
inhibition in immunosuppressed or immunocompromised patients with
advanced cutaneous squamous cell carcinoma (CSCC): Data from
prospective CemiplimAb-rwlc Survivorship and Epidemiology
(C.A.S.E.) study
- Abstract 9566: Health-related
quality of life (HRQoL) in patients (pts) with locally advanced
basal cell carcinoma (laBCC) treated with cemiplimab: analysis of a
phase II, open-label clinical trial
- Abstract e18830: Budget impact (BI)
analysis of cemiplimab-rwlc for advanced basal cell carcinoma (BCC)
after hedgehog inhibitor (HHI) therapy in the United States
Other Sanofi studies in Non-Melanoma Skin
Cancer
- Abstract e18740: Frequency, characteristics, and subsequent
treatment (Tx) of real-world patients (pts) who discontinue
hedgehog inhibitors (HHI) as first-line (1L) systemic Tx for
advanced basal cell carcinoma (aBCC)
- Abstract e18742: Outcomes in
patients (pts) with advanced basal cell carcinoma (aBCC) who
discontinued hedgehog inhibitors (HHI) as first-line (1L) systemic
treatment (Tx) in a US community oncology setting: A retrospective
observational study
Libtayo in Non-small Cell Lung Cancer
- Abstract 9085: Cemiplimab
monotherapy as first-line (1L) treatment of patients with brain
metastases from advanced non-small cell lung cancer (NSCLC) with
programmed cell death-ligand 1 (PD-L1) ≥50%; EMPOWER-Lung 1
subgroup analysis
- Abstract 9078: Patient-reported
symptoms, functioning, and quality of life (QoL) in patients
treated with cemiplimab monotherapy for first-line treatment of
advanced NSCLC with PD-L1 ≥50%: Results from EMPOWER-Lung 1
study
- Abstract e18817: Budget impact (BI)
analysis of cemiplimab for first-line (1L) advanced non-small cell
lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1)
≥50% in the United States
- Abstract e21091: Network
meta-analysis (NMA) of immuno-oncology (IO) monotherapy (mono) as
first-line (1L) treatments (txs) for advanced non-small cell lung
cancer (NSCLC) with PD-L1 expression ≥50%
Libtayo is being jointly developed by Sanofi and
Regeneron under a global collaboration agreement.
Longer term data and
new analyses for Sarclisa®
(isatuximab-irfc) further
strengthen its efficacy
profile, including for elderly
patients and patients with
high-risk cytogenetic
abnormalities
- Abstract 8017: Updates from
ICARIA-MM, a Phase 3 study of isatuximab (Isa) plus pomalidomide
and low-dose dexamethasone (Pd) versus Pd in relapsed and
refractory multiple myeloma (RRMM)
- Abstract 8042: Isatuximab plus
carfilzomib and dexamethasone in relapsed multiple myeloma patients
with high-risk cytogenetics: IKEMA subgroup analysis
- Abstract 8026: Isatuximab plus
carfilzomib and dexamethasone versus carfilzomib and dexamethasone
in elderly patients with relapsed multiple myeloma: IKEMA subgroup
analysis
- Abstract e20015: Isatuximab plus
carfilzomib and dexamethasone in East Asian patients with relapsed
multiple myeloma: IKEMA subgroup analysis
- Abstract 8034: Isatuximab plus
carfilzomib and dexamethasone in patients with relapsed multiple
myeloma according to prior lines of treatment and refractory
status: IKEMA subgroup analysis
Biomarker research
for tusamitamab
ravtansine, an
early-stage,
potential first-in-class
investigational anti-CEACAM5
antibody drug conjugate for advanced non-small cell lung
cancer*
- Abstract e21030: Validation of an
immunohistochemical assay, CEACAM5 IHC 769, under development for
use with the antibody-drug conjugate tusamitamab ravtansine
(SAR408701)
Safety, pharmacokinetic and
pharmacodynamic data with our investigational transforming growth
factor beta
(TGF-b)*
- Abstract 2510: Safety,
pharmacokinetic and pharmacodynamic results from dose escalation of
SAR439459, a TGFβ inhibitor, as monotherapy or in combination with
cemiplimab in a phase 1/1b study
Early data with investigational
anti-ICOS antibody, KY1044, submitted by
Kymab, a Sanofi
company*
- Abstract 2624: A phase 1/2
open-label study of KY1044, an anti-ICOS antibody with dual
mechanism of action, as single agent and in combination with
atezolizumab, in adult patients with advanced malignancies
- Abstract 2626: KY1044 to target the
ICOS pathways inducing intratumoral Treg depletion and agonism of
effector T cells: Preliminary pharmacodynamic markers from a phase
1/2 multicenter trial
Independent research
supported by Sanofi
Jevtana (Cabazitaxel) |
Abstract 5059 |
First results from a randomized Phase II study of cabazitaxel (CBZ)
versus an androgen receptor targeted agent (ARTA) in patients with
poor-prognosis castration-resistant prostate cancer (mCRPC) |
Abstract 1008 |
Randomised multicentre trial of 3 weekly Cabazitaxel versus weekly
Paclitaxel chemotherapy in the first line treatment of HER2
negative metastatic breast cancer (MBC) |
Abstract e17027 |
Prostate cancer intensive, non-cross reactive therapy (PRINT) for
CRPC: interim analysis of efficacy endpoints |
Click here to view these abstracts along with
the full digital program located in the ASCO Meeting Library.
*These assets are currently under investigation
and their safety and efficacy has not been fully evaluated by any
health authority.
About Sanofi Sanofi is dedicated to
supporting people through their health challenges. We are a global
biopharmaceutical company focused on human health. We prevent
illness with vaccines, provide innovative treatments to fight pain
and ease suffering. We stand by the few who suffer from rare
diseases and the millions with long-term chronic
conditions. With more than 100,000 people in 100 countries,
Sanofi is transforming scientific innovation into healthcare
solutions around the globe. Sanofi, Empowering Life |
Sanofi Media Relations Contact
Sally Bain Tel.: +1 (781) 264-1091Sally.Bain@sanofi.com
|
Sanofi Investor Relations Contacts
ParisEva Schaefer-JansenArnaud
Delepine Sanofi Investor Relations
Contacts North AmericaFelix LauscherFara BerkowitzSuzanne
Greco Sanofi IR main line:Tel.: +33 (0)1 53
77 45
45investor.relations@sanofi.comhttps://www.sanofi.com/en/investors/contact |
Sanofi Forward-Looking
StatementsThis press release contains forward-looking
statements as defined in the Private Securities Litigation Reform
Act of 1995, as amended. Forward-looking statements are statements
that are not historical facts. These statements include projections
and estimates and their underlying assumptions, statements
regarding plans, objectives, intentions and expectations with
respect to future financial results, events, operations, services,
product development and potential, and statements regarding future
performance. Forward-looking statements are generally identified by
the words “expects”, “anticipates”, “believes”, “intends”,
“estimates”, “plans” and similar expressions. Although Sanofi’s
management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned
that forward-looking information and statements are subject to
various risks and uncertainties, many of which are difficult to
predict and generally beyond the control of Sanofi, that could
cause actual results and developments to differ materially from
those expressed in, or implied or projected by, the forward-looking
information and statements. These risks and uncertainties include
among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post
marketing, decisions by regulatory authorities, such as the FDA or
the EMA, regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential
of such product candidates, the fact that product candidates if
approved may not be commercially successful, the future approval
and commercial success of therapeutic alternatives, Sanofi’s
ability to benefit from external growth opportunities, to complete
related transactions and/or obtain regulatory clearances, risks
associated with intellectual property and any related pending or
future litigation and the ultimate outcome of such litigation,
trends in exchange rates and prevailing interest rates, volatile
economic and market conditions, cost containment initiatives and
subsequent changes thereto, and the impact that COVID-19 will have
on us, our customers, suppliers, vendors, and other business
partners, and the financial condition of any one of them, as well
as on our employees and on the global economy as a whole. Any
material effect of COVID-19 on any of the foregoing could also
adversely impact us. This situation is changing rapidly and
additional impacts may arise of which we are not currently aware
and may exacerbate other previously identified risks. The risks and
uncertainties also include the uncertainties discussed or
identified in the public filings with the SEC and the AMF made by
Sanofi, including those listed under “Risk Factors” and “Cautionary
Statement Regarding Forward-Looking Statements” in Sanofi’s annual
report on Form 20-F for the year ended December 31, 2020. Other
than as required by applicable law, Sanofi does not undertake any
obligation to update or revise any forward-looking information or
statements. |
Sanofi (EU:SAN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sanofi (EU:SAN)
Historical Stock Chart
From Apr 2023 to Apr 2024